Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future

Area of Science:

• Cardiology
• Pharmacology
• Medical Research

Background:

• Cardiovascular disease (CVD) remains a primary global cause of death.
• Elevated low-density lipoprotein cholesterol (LDL-C) is a significant CVD risk factor.
• Clinical trials confirm LDL-C reduction effectively lowers cardiovascular events.

Purpose of the Study:

• To review the historical development and current landscape of LDL-C lowering medications.
• To highlight the progression from traditional therapies to novel pharmacological agents.
• To introduce emerging treatments, including oral PCSK9 inhibitors.

Main Methods:

• Literature review of landmark clinical trials and pharmacological advancements.
• Discussion of drug classes targeting LDL-C reduction.
• Overview of therapeutic evolution from bile acid sequestrants to PCSK9 inhibitors.

Main Results:

• Significant reduction in cardiovascular events is achieved with LDL-C lowering therapies.
• Therapeutic efficacy generally correlates with the degree of LDL-C reduction.
• A pipeline of innovative LDL-C lowering medications is advancing through clinical trials.

Conclusions:

• The evolution of LDL-C lowering medications has significantly impacted CVD management.
• Novel therapies, such as PCSK9 inhibitors, offer new strategies for achieving target LDL-C levels.
• Ongoing research, including phase 3 trials for oral PCSK9 inhibitors, promises further advancements in CVD prevention.